Initiative for Vaccine Research (IVR)

NIAID/WHO Workshop on Heterologous Prime-Boost Strategies for HIV, Malaria and Tuberculosis Vaccines

17-18 April 2012, Washington DC, USA

This technical meeting brought together leading scientists, vaccine researchers and developers from academia, government agencies and industry working on heterologous prime-boost strategies for immunization primarily in HIV, malaria and TB. Work on ebola and hepatitis C was also presented. Heterologous prime-boost immunization refers to consecutive administration of two different vaccine platforms (e.g., recombinant vectors, recombinant proteins) providing the same or overlapping antigenic regions of the target organism. This meeting followed from a WHO recommendation that further information-sharing was desirable among vaccine development communities, particularly across HIV, malaria and tuberculosis. As there is no regular forum for interaction among the vaccine research communities for these 3 diseases, NIAID/WHO identified leading projects in advanced pre-clinical or clinical evaluation, and convened scientists across the disease areas.

This first convening of the HIV, malaria and tuberculosis vaccine communities may foster collaborations, and enabled sharing of technical lessons learned. Heterologous prime-boost was chosen because leading clinical projects in the 3 disease areas follow this approach, and the outcomes are potentially relevant across disease areas, although the immunological objectives differ.

Each speaker was asked to give a synthetic talk including lessons learned from their experiences that are of wider relevance. The scientists have kindly given permission for these presentations to be made available on this website.

Opening and Closing Comments were made by Meeting Chair Stanley Plotkin

Session 1: Infection Biology: HIV, Malaria, TB

Moderator Bob Seder

Session 2: DNA Priming

Moderator Nicole Frahm

Session 3: BCG Priming

Moderator: Tom Evans

Session 4: Recombinant Poxviruses

Moderator: Mary Marovich

Session 5: Recombinant Adenovirus

Moderator: Tom Richie

Session 6: Recombinant Proteins with Novel Adjuvants

Moderator: Dennis Klinman

Session 7: Panel Discussion

Moderator: Mike Brennan

Share
Email Twitter Facebook Google Delicious LinkedIn
More...